Reliance bull run: RIL adds Rs 4.4 lakh crore in 2025 as telecom and O2C fire together; Should you buy or sell? Here’s what experts say

After a lacklustre 2024, Reliance Industries is staging one of its sharpest rebounds since the Covid year of 2020, with a broad set of triggers across energy, telecom and retail fueling a powerful rerating. The Nifty heavyweight has jumped more than 26% in 2025, adding Rs 4.4 lakh crore to its valuation and pushing its…

Read More

Market slide hits Dalal Street’s richest: Big investors see portfolio erosion; few outliers buck the trend–check detail

Indian investors saw their portfolios shrink in the July-September quarter. A market downturn impacted most major investors, leading to substantial mark-to-market losses. Nemish Shah emerged as a notable gainer, increasing his portfolio value significantly. Other investors like Vijay Kedia and Madhusudan Kela reported modest gains. The late Rakesh Jhunjhunwala’s family holdings also saw a decline….

Read More

‘Heightened exuberance’: RBI bulletin warns about overheated global markets; says fiscal–monetary push to lift investment in India

Fiscal, monetary and regulatory measures are expected to pave the way for a “virtuous cycle” of higher private investment-led growth, even as global trade uncertainties and external sector headwinds persist, the Reserve Bank of India (RBI) said in its November Bulletin released on Monday.An article on State of the Economy in the Bulletin noted that…

Read More

Crash course! Cryptocurrency market’s $1 trillion rout hits Trump family fortune; how much loss crypto-linked holdings have caused?

The Trump-associated memecoin has seen a huge 25% decline since August. (AI image) The recent crash in the cryptocurrency market has cost US President Donald Trump and his family several millions of dollars. During Donald Trump’s second presidential term, digital assets have significantly altered his family’s wealth and portfolio. But the perils and instability associated…

Read More

US markets today: Wall Street opens higher as rate-cut hopes rise; holiday-shortened week keeps traders cautious

US stocks opened firmer on Monday as expectations of a December rate cut lifted sentiment at the start of a holiday-shortened trading week. The S&P 500 advanced 0.7 per cent, extending Friday’s rebound, while the Dow Jones Industrial Average gained 138 points and the Nasdaq climbed 1.1 per cent, AP reported.The early uptick came despite…

Read More

Capex momentum: Adani Group adds Rs 67,870 crore in new assets during H1; leverage stays below guidance despite expansion

Adani Group reported its strongest first-half performance in years, powered by record capital expenditure and higher operating earnings across its core infrastructure portfolio. The conglomerate added Rs 67,870 crore of gross assets in the first six months of FY26, taking its total asset base to Rs 6.77 lakh crore, and said it remains on track…

Read More

Warren’s wisdom! Learn how to build a long-term career the Warren Buffett way — essential tips you should know

Warren Buffett may be best known for shaping Berkshire Hathaway into a $1 trillion giant, but his greatest lessons extend far beyond investing. Earlier this month, the 95-year-old signalled his retirement and wrote his final shareholder letter, marking the end of six decades of steady, disciplined growth. Writing for ET Wealth, Devashish Chakravarty described Buffett’s…

Read More

Credit pulse: NBFCs eye steady AUM rise as firms adopt risk-calibrated lending; unsecured and MSME segments face strain

A steady expansion in retail credit demand is expected to keep non-bank finance companies on an 18 per cent growth path, even as lenders turn more selective amid rising borrower leverage, Crisil Ratings has said. The agency noted that NBFCs are moderating their stance in pockets such as unsecured MSME loans, where repayment stress is…

Read More

Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout

Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The approval covers all EU member states as well as Iceland, Liechtenstein and Norway under the European Economic Area framework.The company said AVT03 is a biosimilar version of Prolia…

Read More